Jasper Therapeutics
JSPR
55 hedge funds and large institutions have $35.2M invested in Jasper Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 15 closing their positions.
570% more call options, than puts
Call options by funds: $449K | Put options by funds: $67K
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
8% less funds holding
Funds holding: 60 → 55 (-5)
26% less capital invested
Capital invested by funds: $47.8M → $35.2M (-$12.7M)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
55.32% less ownership
Funds ownership: 124.01% → 68.69% (-55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.45M |
| 2 |
Morgan Stanley
New York
|
+$2.37M |
| 3 |
Millennium Management
New York
|
+$1.42M |
| 4 |
ACA
Acorn Capital Advisors
New York
|
+$811K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$705K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$3.15M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.6M |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$2.45M |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$1.45M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.18M |
JSPR Hedge Fund Activity: Q4 2025 in Review
55 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2025, worth a combined $35.2M — down 26% from $47.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of JSPR and 11 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 22 added.
The largest buyer was Goldman Sachs, adding an estimated $3.45M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $3.15M sold.
- 55 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2025, down from 60 in Q3 2025.
- Funds reported $35.2M of Jasper Therapeutics stock for Q4 2025, down 26% quarter-over-quarter.
- 11 funds opened new Jasper Therapeutics positions in Q4 2025 and 15 closed out, a net change of -4 holders.
- The largest Jasper Therapeutics buyer in Q4 2025 was Goldman Sachs, an estimated $3.45M added.
- The largest Jasper Therapeutics seller in Q4 2025 was Kingdon Capital Management, an estimated $3.15M sold.
Based on aggregated 13F filings for Q4 2025.